Harness Therapeutics has unveiled its second-generation MISBA® platform, dubbed MISBA Duo, and announced a research collaboration with Ono Venture Investment, the venture arm of Ono Pharmaceutical. According to the company, MISBA Duo enables bimodal modulation — simultaneous upregulation of one target and downregulation of another.
The collaboration will deploy MISBA Duo in a newly launched R&D programme targeting an undisclosed rare triplet repeat disorder. Under the agreement, Harness will develop and evaluate candidate molecules that selectively modulate two biological targets, with the goal of advancing disease-modifying therapies across all disease stages. The programme builds on insights and expertise from Harness’s wholly owned FAN1 programme in Huntington’s Disease, currently in preclinical development.
Ono Venture Investment will fund the initiative and also holds an exclusive option to negotiate rights to any resulting candidates and associated intellectual property related to the rare disorder. Ono had earlier invested in Harness in January 2025 to support the development of its Huntington’s Disease programme.
Harness frames MISBA Duo as an evolution of its original MISBA technology, expanding from controlled upregulation to dual modulation. The company claims this advance could broaden opportunities for novel therapies in neurodegenerative and central nervous system disorders.
